NO20061662L - Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament - Google Patents

Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament

Info

Publication number
NO20061662L
NO20061662L NO20061662A NO20061662A NO20061662L NO 20061662 L NO20061662 L NO 20061662L NO 20061662 A NO20061662 A NO 20061662A NO 20061662 A NO20061662 A NO 20061662A NO 20061662 L NO20061662 L NO 20061662L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
receptor antagonist
steroidal anti
inflammatory drug
active ingredient
Prior art date
Application number
NO20061662A
Other languages
English (en)
Norwegian (no)
Inventor
Nigel Boughton-Smith
Simon Cruwys
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20061662L publication Critical patent/NO20061662L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20061662A 2003-09-18 2006-04-11 Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament NO20061662L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302488A SE0302488D0 (sv) 2003-09-18 2003-09-18 New combination
PCT/SE2004/001334 WO2005025571A1 (fr) 2003-09-18 2004-09-15 Composition pharmaceutique comprenant un antagoniste du recepteur p2x7 et un medicament anti-inflammatoire non steroidien.

Publications (1)

Publication Number Publication Date
NO20061662L true NO20061662L (no) 2006-04-11

Family

ID=29212490

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061662A NO20061662L (no) 2003-09-18 2006-04-11 Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament

Country Status (20)

Country Link
US (1) US20070082930A1 (fr)
EP (1) EP1663224A1 (fr)
JP (1) JP2007505900A (fr)
KR (1) KR20060086942A (fr)
CN (1) CN1859911A (fr)
AR (1) AR045783A1 (fr)
AU (1) AU2004271886B2 (fr)
BR (1) BRPI0414558A (fr)
CA (1) CA2538416A1 (fr)
IL (1) IL173913A0 (fr)
IS (1) IS8396A (fr)
MX (1) MXPA06002722A (fr)
NO (1) NO20061662L (fr)
NZ (1) NZ545964A (fr)
RU (1) RU2338556C2 (fr)
SE (1) SE0302488D0 (fr)
TW (1) TW200526199A (fr)
UY (1) UY28517A1 (fr)
WO (1) WO2005025571A1 (fr)
ZA (1) ZA200602260B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
WO2004105797A1 (fr) * 2003-05-29 2004-12-09 Astrazeneca Ab Nouvelle combinaison
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
EP1906960A4 (fr) * 2005-07-11 2010-03-10 Astrazeneca Ab Nouvelle combinaison 1
WO2007008157A1 (fr) * 2005-07-11 2007-01-18 Astrazeneca Ab Nouvelle combinaison 2
WO2007098086A2 (fr) * 2006-02-17 2007-08-30 Avalon Pharmaceuticals Dérivés d'hydroxypipéridine et leurs utilisations
GB0724258D0 (en) * 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
WO2009074518A1 (fr) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinaisons formées de modulateurs au prolinamide du récepteur p2x7 et d'autres agents thérapeutiques
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
CA2783236C (fr) 2009-12-08 2020-03-10 Vanderbilt University Procedes et compositions ameliores destines au prelevement de veines et a l'autogreffe
EP2542670A2 (fr) 2010-03-05 2013-01-09 President and Fellows of Harvard College Compositions de cellules dendritiques induites et utilisations associées
US20140322193A1 (en) * 2011-12-02 2014-10-30 Michael Kaleko Therapies for Disorders of the Cornea and Conjunctiva
US11000495B2 (en) 2014-09-10 2021-05-11 GSK Consumer Healthcare S.A. Topical diclofenac sodium compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
CZ296163B6 (cs) * 1996-05-20 2006-01-11 Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CZ20013608A3 (cs) * 1999-04-09 2002-05-15 Astrazeneca Ab Adamantanové deriváty
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
CN1434713A (zh) * 1999-12-22 2003-08-06 法马西亚公司 环加氧酶－2抑制剂的缓释制剂
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
CZ20042A3 (en) * 2001-07-02 2004-04-14 Akzo Nobel N. V. Tetrahydroquinoline derivatives
WO2003042190A1 (fr) * 2001-11-12 2003-05-22 Pfizer Products Inc. Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
WO2004105797A1 (fr) * 2003-05-29 2004-12-09 Astrazeneca Ab Nouvelle combinaison
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
BRPI0414558A (pt) 2006-11-07
JP2007505900A (ja) 2007-03-15
RU2006112423A (ru) 2007-11-10
WO2005025571A1 (fr) 2005-03-24
KR20060086942A (ko) 2006-08-01
IL173913A0 (en) 2006-07-05
AR045783A1 (es) 2005-11-16
TW200526199A (en) 2005-08-16
CA2538416A1 (fr) 2005-03-24
CN1859911A (zh) 2006-11-08
RU2338556C2 (ru) 2008-11-20
EP1663224A1 (fr) 2006-06-07
SE0302488D0 (sv) 2003-09-18
US20070082930A1 (en) 2007-04-12
IS8396A (is) 2006-04-03
AU2004271886A1 (en) 2005-03-24
NZ545964A (en) 2009-09-25
AU2004271886B2 (en) 2008-03-20
ZA200602260B (en) 2007-07-25
UY28517A1 (es) 2005-04-29
MXPA06002722A (es) 2006-06-06

Similar Documents

Publication Publication Date Title
NO20061662L (no) Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament
NO20073259L (no) Nye 4-arylaminopyndondenvater som MEK inhibrtorer av hyperproliferende lidelser
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
UY26926A1 (es) Derivados de la quinolina y quinazolina
DK2298743T3 (da) p38-Kinaseinhibitorer på grundlag af en 5-leddet heterocyclisk ring
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
WO2005011586A3 (fr) Traitement et prevention d'accidents cardiovasculaires
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
WO2006074265A3 (fr) Therapie combinee et compositions pharmaceutiques utilisees dans le traitement des troubles inflammatoires
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
NO20071806L (no) Tabletter med steds- og tidsregulert gastrointestinal frigivelse av aktiv bestanddel.
MXPA05012705A (es) Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
DK1492773T3 (da) 4-(Heterocyclyl)-benzensulfoximin-forbindelser til behandling af inflammation
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
WO2006100213A8 (fr) Composition comprenant un antagoniste du recepteur du thromboxane et un inhibiteur de la thromboxane synthase et un inhibiteur de cox-2 combines
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
UY30029A1 (es) Derivados de piperidina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones
WO2006064228A3 (fr) Composes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application